Press Releases

Date Title and Summary Additional Formats
Toggle Summary Retrophin Joins Participants from Around the World in Recognizing Rare Disease Day® 2017
Retrophin Joins Participants from Around the World in Recognizing Rare Disease Day ® 2017   SAN DIEGO (February 28, 2017) – Retrophin, Inc. (NASDAQ: RTRX) today joins patients, advocates, healthcare professionals, researchers, public health authorities and the biopharmaceutical
View HTML
Toggle Summary Retrophin to Report Fourth Quarter and Full Year 2016 Financial Results
SAN DIEGO , Feb. 15, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced it will report fourth quarter and full year 2016 financial results on Wednesday, March 1, 2017 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss
View HTML
Toggle Summary Retrophin Appoints William Rote Senior Vice President, Research and Development
SAN DIEGO , Feb. 13, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced William "Bill" Rote, Ph.D. has been appointed senior vice president, research and development, effective immediately. Dr. Rote will oversee all aspects of the Company's R&D organization, with special focus
View HTML
Toggle Summary Retrophin Provides Corporate Update and 2017 Preview
FDA discussions on sparsentan planned for January; RE-024 advancing with Phase 3 trial for the treatment of PKAN Preliminary Full-Year 2016 Revenue of Approximately $134 Million SAN DIEGO , Jan. 09, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that, based on preliminary
View HTML
Toggle Summary Retrophin Appoints Elizabeth Reed General Counsel
SAN DIEGO , Jan. 04, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced Elizabeth Reed has been appointed general counsel and corporate secretary, effective immediately. Ms. Reed will be responsible for overseeing the Company's general legal, intellectual property, government
View HTML
Toggle Summary Retrophin to Present at the 35th Annual J.P. Morgan Healthcare Conference
SAN DIEGO , Dec. 29, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that Stephen Aselage , chief executive officer, will present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 12, 2017 at 10:30 a.m. PT .
View HTML
Toggle Summary Retrophin to Present at the BMO Capital Markets Healthcare Conference
SAN DIEGO , Nov. 30, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that Stephen Aselage , chief executive officer, will present at the BMO Capital Markets Prescription for Success Healthcare Conference in New York City on Wednesday, December 14, 2016 at 10:30 a.m. ET .
View HTML
Toggle Summary Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016
Significant reduction of proteinuria compared to irbesartan Statistically significant difference in modified partial remission; complete remission also observed Further analysis supports sparsentan generally safe and well-tolerated SAN DIEGO , Nov. 19, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc.
View HTML
Toggle Summary Retrophin Reaches Agreement with FDA under Special Protocol Assessment for Pivotal Trial Evaluating RE-024 in PKAN
Phase 3 trial expected to initiate before year-end 2016
View HTML
Toggle Summary Retrophin Reports Third Quarter 2016 Financial Results
Positive top-line results from DUET announced in September; additional data to be presented at ASN Kidney Week 2016 Third quarter revenues increased 21 percent year-over-year SAN DIEGO , Nov. 03, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today reported its third quarter 2016 financial
View HTML